Table 1 Clinical characteristics of 53 T-MN patients and comparison with other study groups
From: Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea
Characteristic | SNUH (n = 53) | Singhal (n = 129) | SEER (n = 1093) | Nishiyama (n = 13) |
|---|---|---|---|---|
Age at diagnosis (years) | Inclusion of pediatric patients* Yes: 56.5 (1.8–82.4) No: 60.3 (20.7–82.4) | 71.1 (20.7–89.9) | 65 (20–97) | 65 (24–76) |
Age group | ||||
< 20 | 7 (13.2) | 0 | 0 | |
20–39 | 5 (9.4) | NA | 68 (6.2) | 4 (30.8) |
40–59 | 18 (34.0) | NA | 317 (29.0) | 2 (15.4) |
60–79 | 20 (37.7) | NA | 606 (55.4) | 7 (53.8) |
≥ 80 | 3 (5.7) | NA | 102 (9.3) | 0 |
Sex | ||||
Male | 28 (52.8) | 73 (56.6) | 486 (44.5) | NA |
Female | 25 (47.2) | 56 (43.4) | 607 (55.5) | NA |
Race | Korean: 51 (96.2) Others: 2 (3.8) | NA | White: 963 (88.1) Black: 69 (6.3) Other: 61 (5.6) | NA |
Primary disease | ||||
Non-Hodgkin lymphoma† | 16 (30.2) | 49 (40.0) | 341 (33.8) | 6 (46.2) |
Plasma cell dyscrasia (plasma cell myeloma, etc.) | 4 (7.5) | 11 (8.5) | 52 (5.2) | 2 (15.4) |
Chronic lymphocytic leukemia | 1 (1.9) | 5 (3.9) | 31 (3.0) | 0 |
Breast cancer | 8 (15.1) | 16 (12.4) | 208 (20.6) | 0 |
Others | 7 (13.2) | 10 (7.8) | 313 (30.6) | 3 (23.1) |
Acute myeloid leukemia | 5 (9.4) | 1 (0.8) | NA | 0 |
Bone/soft tissue neoplasm | 5 (9.4) | 3 (2.3) | 43 (4.3) | 2 (15.4) |
Germ cell tumor | 5 (9.4) | 1 (0.8) | NA | 2 (15.4) |
Colorectal cancer | 4 (7.5) | 9 (7.0) | NA | 0 |
Multiple primary tumors | 2 (3.8) | 6 (4.7) | NA | 0 |
Acute lymphoblastic leukemia | 1 (1.9) | 4 (3.1) | 36 (3.6) | 0 |
Sole autoimmune disease | 0 | 13 (10.1) | NA | 0 |
Hodgkin lymphoma | 0 | 3 (2.3) | 30 (2.9) | 0 |
Prostate cancer | 0 | 14 (10.9) | 43 (4.2) | 0 |
Latency (months) | 52.0 (12.0–309.7) | NA | NA | 12 (4–48) |
Duration of past cytotoxic therapy (months) | 18.6 (1.2–122.8) | NA | NA | NA |
Past cytotoxic therapy | Chemotherapy Yes: 750 (68.6) No/unknown: 343 (31.4) | |||
Sole chemotherapy | 35 (66.0) | 59 (45.7) | NA | NA |
Sole radiotherapy | 0 | 28 (21.7) | NA | NA |
Chemotherapy and radiotherapy | 18 (34.0) | 42 (32.6) | NA | NA |
Alkylating agent | 45 (84.9) | NA | NA | 12 (92.3) |
Topoisomerase II inhibitor | 36 (67.9) | NA | NA | 2 (15.4) |
Antimetabolite | 9 (17.0) | NA | NA | NA |
Antitubulin agent | 25 (47.2) | NA | NA | NA |
Autologous PBSCT | 9 (17.0) | 21 (16.3) | NA | NA |
Allogenic PBSCT | 3 (5.7) | NA | NA | NA |
T-MN subtype | ||||
MDS | 28 (52.8) | 83 (64.3) | NA | 9 (69.2) |
MDS/MPN | 1 (1.9) | 11 (8.5) | NA | 2 (15.4) |
AML | 24 (45.3) | 34 (26.4) | NA | 2 (15.4) |
Cytogenetic abnormalities‡ | ||||
−5/del(5q) | 15 (28.3) | 5 (3.9) | NA | 4 (30.8) |
−7/del(7q) | 23 (43.4) | 23 (17.8) | NA | 4 (30.8) |
−17/del(17p) | 5 (9.4) | NA | NA | 1 (7.7) |
PML-RARA | 4 (7.5) | 2 (1.6) | NA | 0 |
KMT2A rearrangement§ | 4 (7.5) | 4 (3.1) | NA | 0 |
RUNX1 rearrangement | 1 (1.9) | NA | NA | 0 |
MECOM rearrangement | 3 (5.7) | NA | NA | 1 (7.7) |
Chromosome 3 abnormalities§ | 0 | 2 (1.6) | NA | 0 |
Complex karyotype (≥ 3 abnormalities) | 25 (47.2) | 36 (27.9) | NA | 8 (61.5) |
Normal karyotype | 6 (11.3) | NA | NA | 2 (15.4) |
Not assessed | 2 (3.8) | NA | NA | 0 |
Overall survival (months) | Inclusion of pediatric patients* Yes: 10.6 (0.2–102.4) No: 9.2 (0.2–102.4) | 10.6 (9.1–13.6) | NA | NA |